Trails Edge Capital Partners, LP 13F: Portfolio & Holdings
Trails Edge Capital Partners, LP (SEC CIK 0002077247) reported 35 positions with a combined market value of $0.6 billion in its most recent SEC Form 13F-HR filing (as of Q2 2026). The Atlanta-based hedge fund has a Healthcare sector tilt, which represents 89.9% of its exposure.
Its largest holdings are Lb Pharmaceuticals INC (LBRX) at 7.8%, Nurix Therapeutics INC (NRIX) at 6.1%, and Immunocore Hldgs PLC (IMCR) at 5.4%.
The largest exit was Vaxcyte INC (PCVX) . See the fund’s full Q2 2026 buys, sells, and portfolio changes →
Based on published SEC 13F filings, Trails Edge Capital Partners's closest peer funds by portfolio overlap are Darwin Global Management, Ltd. (72.4%), Baker Bros. Advisors LP (34.6%), and Caligan Partners LP (32.4%).
- 13F AUM
- $0.6B
- Equity Positions
- 35
- Top-10 Concentration
- 50.3%
- Largest Sector · 89.9%
- Healthcare
- Longest-Held Position · 3 qtrs
- CAMP
- Median Holding Period
- 2 Qtrs
What are Trails Edge Capital Partners’s largest 13F holdings as of Q2 2026?
Largest 13F positions disclosed by Trails Edge Capital Partners, ranked by portfolio weight. Full multi-quarter history and the broader institutional holder base for each ticker linked per row.
| # | Issuer | Ticker | Sector | Weight | Position Value | Detail |
|---|---|---|---|---|---|---|
| 1 | LB PHARMACEUTICALS INC | LBRX | Healthcare | 7.8% | $49.4M | Position History All Holders |
| 2 | NURIX THERAPEUTICS INC | NRIX | Healthcare | 6.1% | $38.2M | Position History All Holders |
| 3 | IMMUNOCORE HLDGS PLC | IMCR | Healthcare | 5.4% | $33.8M | Position History All Holders |
| 4 | FIRST TRACKS BIOTHERAPEUTICS NEW | TRAX | Unknown | 4.8% | $30.5M | Position History All Holders |
| 5 | 4D MOLECULAR THERAPEUTICS IN | FDMT | Healthcare | 4.7% | $29.6M | Position History All Holders |
| 6 | BIOMARIN PHARMACEUTICAL INC NEW | BMRN | Healthcare | 4.7% | $29.3M | Position History All Holders |
| 7 | DESIGN THERAPEUTICS INC | DSGN | Healthcare | 4.6% | $29.0M | Position History All Holders |
| 8 | XENON PHARMACEUTICALS INC | XENE | Healthcare | 4.2% | $26.6M | Position History All Holders |
| 9 | MIRUM PHARMACEUTICALS INC | MIRM | Healthcare | 4.2% | $26.1M | Position History All Holders |
| 10 | INSMED INC NEW | INSM | Healthcare | 3.9% | $24.6M | Position History All Holders |
View Trails Edge Capital Partners's Q2 2026 portfolio changes and trading report →
Portfolio composition
Sectors, concentrations, and a tap-through treemap of every position in the fund's latest 13F.
Holding period analytics
Distribution of holding periods for all 48 stocks the fund has ever held (up to selected quarter):
Which Funds Hold a Similar Portfolio to Trails Edge Capital Partners?
Ranked by percentage of the peer fund's 13F equity portfolio that overlaps with Trails Edge Capital Partners's positions in Q2 2026.
| # | Fund | Shared Positions | Overlap % |
|---|---|---|---|
| 1 | Darwin Global Management, Ltd. | 2 | 72.4% |
| 2 | Baker Bros. Advisors LP | 13 | 34.6% |
| 3 | Caligan Partners LP | 9 | 32.4% |
| 4 | Jones Hill Capital LP | 5 | 30.0% |
| 5 | Paradigm Biocapital Advisors LP | 3 | 25.2% |
| 6 | Frazier Life Sciences Management, L.P. | 6 | 24.3% |
| 7 | Vestal Point Capital, LP | 10 | 18.8% |
| 8 | Eagle Health Investments LP | 5 | 17.4% |
| 9 | Spruce Street Capital LP | 5 | 15.0% |
| 10 | Deep Track Capital, LP | 13 | 13.2% |
How Has Trails Edge Capital Partners's AUM Changed Over Time?
Quarterly 13F-reported AUM for Trails Edge Capital Partners, derived from aggregate reported position market values disclosed to the U.S. SEC.
| Quarter | 13F AUM (USD) | QoQ Change |
|---|---|---|
| Q4 2025 | $405M | – |
| Q1 2026 | $425M | +0.0B |
| Q2 2026 | $630M | +0.2B |
Methodology & FAQ
How We Track Trails Edge Capital Partners Holdings
Our data is systematically aggregated directly from quarterly Form 13F-HR disclosures submitted to the U.S. Securities and Exchange Commission (SEC).
- Who must file: This dataset includes filings from U.S. institutional investment managers, hedge funds, mutual funds, university endowments, and family offices managing at least $100 million in Section 13(f) securities (including equities, options, convertibles, ETFs, and warrants).
- What is included: By regulation, 13F filings include long positions in U.S. exchange-listed stocks, ETFs, shares of closed-end investment companies, and convertible debt, as defined in the SEC's official Section 13(f) securities list . For listed options (calls/puts) the reported value is based on the notional value.
- Metric definition: “Portfolio Weight” shows how much of a fund's total reported 13F portfolio value (excluding listed options) is allocated to a specific position on the reporting date.
- How to use this data: Quarter-over-quarter changes in shares and portfolio weight reflect a combination of active trading and market price movements. These are descriptive metrics of fund allocation, not explicit buy or sell signals.
What does Trails Edge Capital Partners's 13F filing disclose about their portfolio?
A Form 13F-HR filed by Trails Edge Capital Partners with the U.S. SEC discloses all long positions in Section 13(f) securities (U.S.-listed equities, ETFs, closed-end funds, and listed put/call options) held at quarter-end with a market value of at least $200,000 or 10,000 or more shares. Pactolio aggregates these filings to surface the manager’s reported portfolio weights, share counts, and quarter-over-quarter portfolio changes in a structured format. The filing represents a point-in-time snapshot of disclosed long-side exposure, not a real-time or complete view of the fund’s total book.
How do you measure conviction in Trails Edge Capital Partners's portfolio allocations?
Conviction is measured by portfolio weight, the percentage of Trails Edge Capital Partners’s total reported 13F market value allocated to a given position, rather than by absolute share count or dollar value alone. A position representing a disproportionately large share of the fund’s disclosed book signals high-conviction allocation, regardless of whether it ranks among the fund’s largest absolute holdings.
What is excluded from Trails Edge Capital Partners's 13F: short positions, swaps, and derivatives?
SEC Form 13F requires disclosure of long positions only. Specifically excluded are: short interest, total return swaps, credit default swaps, and all OTC derivatives, none of which appear in 13F filings regardless of position size. Listed put and call options must be disclosed but are excluded from portfolio weight calculations on this platform so that reported weights reflect direct equity exposure and remain comparable across filers. This means Trails Edge Capital Partners’s 13F represents the reported long book, which may differ materially from its net economic exposure.
When is Trails Edge Capital Partners's 13F data available, and how large is the reporting lag?
Investment managers must submit Form 13F within 45 calendar days of each quarter-end (the T+45 deadline). Pactolio ingests filings directly from SEC EDGAR as they are published, so managers who file early appear in our system before the deadline, while late filers are captured on their actual filing date. The quarter label shown at the top of this page reflects the most recently processed 13F cycle for Trails Edge Capital Partners. The inherent reporting lag means the data always reflects positions as of the prior quarter-end, not current holdings.
Who must file a Form 13F with the SEC, and does Trails Edge Capital Partners qualify?
Under SEC Rule 13f-1, any investment manager (including hedge funds, family offices, registered investment advisers, pension funds, and university endowments) that exercises investment discretion over $100 million or more in Section 13(f) securities at any point during a calendar year must file Form 13F for that year. Trails Edge Capital Partners meets this threshold, which is why its holdings are publicly disclosed and accessible on this platform. The $100 million threshold is evaluated on a rolling basis, meaning new filers can enter and existing filers can exit the disclosure regime as AUM crosses that boundary.